A new trading day began on Friday, with Acrivon Therapeutics Inc (NASDAQ: ACRV) stock price up 1.74% from the previous day of trading, before settling in for the closing price of $1.15. ACRV’s price has ranged from $1.09 to $10.16 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 7.47%. With a float of $22.14 million, this company’s outstanding shares have now reached $31.35 million.
Considering the fact that the conglomerate employs 78 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Acrivon Therapeutics Inc (ACRV) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Acrivon Therapeutics Inc is 29.41%, while institutional ownership is 56.77%. The most recent insider transaction that took place on Apr 30 ’25, was worth 617,412. In this transaction 10% Owner of this company sold 437,881 shares at a rate of $1.41, taking the stock ownership to the 3,403,025 shares. Before that another transaction happened on May 01 ’25, when Company’s 10% Owner sold 298,886 for $1.34, making the entire transaction worth $400,507. This insider now owns 3,104,139 shares in total.
Acrivon Therapeutics Inc (ACRV) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.58 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.47% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 3.46% during the next five years compared to -74.96% drop over the previous five years of trading.
Acrivon Therapeutics Inc (NASDAQ: ACRV) Trading Performance Indicators
Here are Acrivon Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 11.17.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.22, a number that is poised to hit -0.57 in the next quarter and is forecasted to reach -2.31 in one year’s time.
Technical Analysis of Acrivon Therapeutics Inc (ACRV)
Compared to the last year’s volume of 0.44 million, its volume of 0.79 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 31.01%. Additionally, its Average True Range was 0.17.
During the past 100 days, Acrivon Therapeutics Inc’s (ACRV) raw stochastic average was set at 1.16%, which indicates a significant decrease from 24.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.79% in the past 14 days, which was lower than the 163.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.1738, while its 200-day Moving Average is $5.7653. Nevertheless, the first resistance level for the watch stands at $1.1833 in the near term. At $1.1967, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.2233. If the price goes on to break the first support level at $1.1433, it is likely to go to the next support level at $1.1167. Now, if the price goes above the second support level, the third support stands at $1.1033.
Acrivon Therapeutics Inc (NASDAQ: ACRV) Key Stats
With a market capitalization of 36.69 million, the company has a total of 31,355K Shares Outstanding. Currently, annual sales are 0 K while annual income is -80,560 K. The company’s previous quarter sales were 0 K while its latest quarter income was -19,680 K.
